CAR-T cell therapy in developing countries: how long should we wait?

Low- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence. However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatment...

Full description

Saved in:
Bibliographic Details
Main Authors: Om P Kurmi, Ramila Shilpakar, Sanjivan Gautam, Balram Gautam, Sudhamshu K C
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e009611.full
Tags: Add Tag
No Tags, Be the first to tag this record!